Article citationsMore>>
T. J. Knott, R. J. Pease, L. M. Powell, S. C. Wallis, S. C. Rall Jr., T. L. Inerarity, B. Blackhart, R. Marcel, D. Johnson, M. Filler, A. J. Lusis, B. J. MCarthy, R. W. Mahley, B. Levy-Wilson and J. Scott, “Complete Protein Sequence and Identification of Structural Domains of Human Apolipoprotein B,” Nature, Vol. 323, No. 6090, 1986, pp. 734-738. doi:10.1038/323734a0
has been cited by the following article:
-
TITLE:
Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients
AUTHORS:
Gen Yoshino, Saburo Nakano, Tomoko Matsumoto, Eiichi Murakami, Toshisuke Morita, Koji Kuboki
KEYWORDS:
Rosuvastatin; Small Dense LDL-Cholesterol (sdLDL); Large Buoyant LDL-C (lbLDL-C); Apolipoprotein (apo) B; Small Dense LDL-Cholesterol (sdLDL)/Large Buoyant LDL-C (lbLDL-C) Ratio
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.3 No.1,
January
12,
2012
ABSTRACT: Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p
Related Articles:
-
Casimir Komenan
-
Moawwad E. A. El-Mikkawy
-
Fossou Jean-Luc Hervé Kouadio, Mamadou Sangare, N’Guessan Nestor Houssou, Marc Ephrem Allialy, Sagbrou Chérubin Djro
-
Ngozi Grace Emordi, Iweriolor Sunday, Onyekpe Basil Obimma
-
Abboud Y. El Kichaoui, Bara’a A. Abu Asaker, Mahmoud W. El-Hindi